Skip to content

Welcome to Discover Pharma! Today is : October 19, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

hepatology

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    CHMP recommends EU approval of Lynavoy for cholestatic pruritus in PBC

    The EMA’s CHMP has recommended EU approval of Lynavoy for [...]

    July 24, 2026
  • Drug Discovery & Development,Opinion & Events

    Vitamin D shown to reduce liver damage by activating TXNIP gene, study finds

    New study shows how the vitamin D/TXNIP axis modulates ductular [...]

    May 5, 2026
  • Biotech & Pharma Business

    Ed Seguine appointed CEO of Target RWE

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Shift Bioscience publishes AI virtual cell framework for target discovery
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top